StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research report released on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the stock. JMP Securities reaffirmed a market outperform rating and issued a $6.00 price objective on […]
StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a report issued on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock. CLLS has been the subject of a number of other reports. JMP Securities reiterated a market outperform rating and issued a $6.00 price objective on shares […]
StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note issued to investors on Friday. The brokerage issued a hold rating on the biotechnology company’s stock. A number of other research firms have also recently issued reports on CLLS. Oppenheimer reaffirmed an outperform rating and issued a $11.00 price target […]
StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, Citigroup dropped their price target on shares of Cellectis from $24.00 to $16.00 and set a buy rating for the company in a […]
StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a report published on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, Citigroup lowered their price target on Cellectis from $24.00 to $16.00 and set a buy rating on the stock in a report on Wednesday, April […]